AMENDMENTS TO THE SPECIFICATION:

Please amend the indicated paragraphs of the specification in accordance with the amendments indicated below.

Page 3: 2nd and 3rd full paragraphs, amend as indicated below:

A transdermal system designed for the administration of a D2-agonist of the above-indicated formula has already been described in WO 94-07468. This system contains the active substance as hydrochloride in a two-phase matrix which is formed substantially by a ~~hydrophobe~~ hydrophobic polymer material, which is present as a continuous phase, with hydrated silicate dispersed therein for taking up the ~~hydrophile~~ hydrophilic drug salt, and additionally contains, or may contain, hydrophobic solvents, permeation-enhancing agents and dispersing agents.

This system has the disadvantage that the active substance salt must be mixed with the silicate in ~~watery~~ aqueous solution, and that an additional emulsifier is necessary to emulsify this aqueous solution with the lipophile ~~plymer~~ polymer, which is dissolved in an organic solvent - commonly hexane, heptane or ethyl acetate. Due to coating problems, it is much more difficult to manufacture transdermal systems using this emulsion. In addition, for such systems only the

salt can be used, since only the salt is sufficiently ~~hydrophile~~ hydrophilic to be soluble in water.

Page 6: 2nd full paragraph, amend as indicated below:

Since, due to its hydrophilic properties, the hydrochloride can pass the barrier of the stratum corneum only poorly, it is necessary in this case to use ~~lipophile~~ lipophilic, monovalent acids such as, for example, oleic acid, which, in the patch matrix, partially converts the hydrochloride into the more lipophilic oleate and which, moreover, generally acts as a permeation enhancer in the skin.

Page 11: 3rd full paragraph, amend as follows:

The dried matrix film is then laminated with a 13-μm-thick polyester film. From the resultant patch laminate the finished patches are then punched out in the desired size and packed in ~~packageing~~ packaging material bags.

Page 13: Paragraph bridging pages 13 and 14, amend as follows:

Optionally, a ~~puffer~~ buffer solution is now added to the active substance solution in order to remove possible excess base. Likewise optionally, the active substance solution can now be filtered; 6.0 g polyvinylpyrrolidone (Kollidon F90, Bayer) in the form of 25% solution (w/w) in ethanol and 250 g of a 70% solution of an

amine-resistant silicone adhesive (Q7-4301, Dow Corning) in heptane are added, and the mass is subsequently homogenised by mechanical stirring.